In-hospital versus out-of-hospital presentation of life-threatening ventricular arrhythmias predicts survival: results from the AVID Registry. Antiarrhythmics Versus Implantable Defibrillators

J Am Coll Cardiol. 1999 Oct;34(4):1111-6. doi: 10.1016/s0735-1097(99)00305-8.

Abstract

Objectives: This study describes the outcomes of patients from the Antiarrhythmics Versus Implantable Defibrillators (AVID) Study Registry to determine how the location of ventricular arrhythmia presentation influences survival.

Background: Most studies of cardiac arrest report outcome following out-of-hospital resuscitation. In contrast, there are minimal data on long-term outcome following in-hospital cardiac arrest.

Methods: The AVID Study was a multicenter, randomized comparison of drug and defibrillator strategies to treat life-threatening ventricular arrhythmias. A Registry was maintained of all patients with sustained ventricular arrhythmias at each study site. The present study includes patients who had AVID-eligible arrhythmias, both randomized and not randomized. Patients with in-hospital and out-of-hospital presentations are compared. Data on long-term mortality were obtained through the National Death Index.

Results: The unadjusted mortality rates at one- and two-year follow-ups were 23% and 31.1% for patients with in-hospital presentations, and 10.5% and 16.8% for those with out-of-hospital presentations (p < 0.001), respectively. The adjusted mortality rates at one- and two-year follow-ups were 14.8% and 20.9% for patients with in-hospital presentations, and 8.4% and 14.1% for those with out-of-hospital presentations (p < 0.001), respectively. The adjusted long-term relative risk for in-hospital versus out-of-hospital presentation was 1.6 (95% confidence interval [CI] 1.3-1.9).

Conclusions: Compared with patients with out-of-hospital presentations of life-threatening ventricular arrhythmias not due to a reversible cause, patients with in-hospital presentations have a worse long-term prognosis. Because location of ventricular arrhythmia presentation is an independent predictor of long-term outcome, it should be considered as an element of risk stratification and when planning clinical trials.

Publication types

  • Clinical Trial
  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Aged
  • Amiodarone / therapeutic use
  • Anti-Arrhythmia Agents / therapeutic use
  • Cardiopulmonary Resuscitation*
  • Defibrillators, Implantable
  • Emergency Medical Services*
  • Female
  • Follow-Up Studies
  • Heart Arrest / mortality
  • Heart Arrest / therapy
  • Hospital Mortality
  • Humans
  • Male
  • Middle Aged
  • Patient Admission*
  • Registries
  • Survival Rate
  • Tachycardia, Ventricular / mortality
  • Tachycardia, Ventricular / therapy*
  • Treatment Outcome
  • United States
  • Ventricular Fibrillation / mortality
  • Ventricular Fibrillation / therapy*

Substances

  • Anti-Arrhythmia Agents
  • Amiodarone